Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache.
Please see full Prescribing Information, including patient selection criteria, and Medication Guide.
TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.